First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.

Matsubara N, Azad AA, Agarwal N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Cislo P, Chang J, Healy CG, Niyazov A, Fizazi K

Open source

DOI: 10.1016/s1470-2045(25)00030-0
Published: 2025 Apr
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00030-0,
  title = {First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.},
  author = {Matsubara N and Azad AA and Agarwal N and Saad F and De Giorgi U and Joung JY and Fong PCC and Jones RJ and Zschäbitz S and Oldenburg J and Shore ND and Dunshee C and Carles J and Fay AP and Cislo P and Chang J and Healy CG and Niyazov A and Fizazi K},
  year = {2025},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(25)00030-0},
  url = {https://doi.org/10.1016/s1470-2045(25)00030-0}
}

RIS

TY  - JOUR
TI  - First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.
AU  - Matsubara N
AU  - Azad AA
AU  - Agarwal N
AU  - Saad F
AU  - De Giorgi U
AU  - Joung JY
AU  - Fong PCC
AU  - Jones RJ
AU  - Zschäbitz S
AU  - Oldenburg J
AU  - Shore ND
AU  - Dunshee C
AU  - Carles J
AU  - Fay AP
AU  - Cislo P
AU  - Chang J
AU  - Healy CG
AU  - Niyazov A
AU  - Fizazi K
PY  - 2025
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(25)00030-0
UR  - https://doi.org/10.1016/s1470-2045(25)00030-0
ER  -

APA

N, M., AA, A., N, A., F, S., U, D. G., JY, J., PCC, F., RJ, J., S, Z., J, O., ND, S., C, D., J, C., AP, F., P, C., J, C., CG, H., A, N., & K, F. (2025). First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00030-0

Source records

pubmed · retrieved 2026-09-27T01:35:49.178Z
europe-pmc · retrieved 2026-09-27T01:35:49.181Z